Sandoz has announced the launch of two new biosimilars in the UK market. MabThera (rituximab) biosimilar Rixathon and Enbrel (etanercept) biosimilar Erelzi will expand access to biologic treatments for a variety of blood cancers and inflammatory conditions in the UK. Rixathon is used to treat conditions such as follicular lymphoma and rheumatoid arthritis. Erelzi is used to treat conditions such as axial spondyloarthritis and plaque psoriasis. By 2020, biosimilar drugs are expected to deliver savings of as much as $110 billion for health systems in the US and Europe.